BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino FZ, Patalano R, De Martino MC, Sciammarella C, Faggiano A, Rocco G, Franco R, Kaltsas GA, Colao A, Pivonello R. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine 2017;56:603-20. [PMID: 27688013 DOI: 10.1007/s12020-016-1079-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Mangili F, Esposito E, Treppiedi D, Catalano R, Marra G, Di Muro G, Barbieri AM, Locatelli M, Lania AG, Mangone A, Spada A, Arosio M, Peverelli E, Mantovani G. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. Front Endocrinol 2022;13:867822. [DOI: 10.3389/fendo.2022.867822] [Reference Citation Analysis]
2 Cui F, Gu S, Gu Y, Yin J, Fang C, Liu L. Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine. BMC Psychiatry 2021;21:388. [PMID: 34348681 DOI: 10.1186/s12888-021-03394-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J Clin Med 2021;10:501. [PMID: 33535394 DOI: 10.3390/jcm10030501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Front Oncol 2020;10:1047. [PMID: 32766136 DOI: 10.3389/fonc.2020.01047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Provvisiero DP, Negri M, de Angelis C, Di Gennaro G, Patalano R, Simeoli C, Papa F, Ferrigno R, Auriemma RS, De Martino MC, Colao A, Pivonello R, Pivonello C. Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. Sci Rep 2019;9:11695. [PMID: 31406139 DOI: 10.1038/s41598-019-48081-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pivonello C, Patalano R, Solari D, Auriemma RS, Frio F, Vitulli F, Grasso LFS, Di Cera M, De Martino MC, Cavallo LM, Cappabianca P, Colao A, Pivonello R. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine 2018;62:663-80. [PMID: 30066286 DOI: 10.1007/s12020-018-1677-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
7 Rapa I, Votta A, Gatti G, Izzo S, Buono NL, Giorgio E, Vatrano S, Napoli F, Scarpa A, Scagliotti G, Papotti M, Volante M. High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. Oncotarget 2018;9:27535-46. [PMID: 29938004 DOI: 10.18632/oncotarget.25541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]